



## **ZAI Lab Enrolls First Patient in Phase 1 Study of ZL-2102**

*Shanghai (17/03/2015)* - ZAI Lab Limited (Zai Lab), a leading innovative biotech company based in China, announced today that it has dosed the first subject in a Phase 1 study of ZL-2102 for the potential treatment of chronic respiratory diseases.

The Phase 1 study of ZL-2102 has been approved by the Bellberry Human Research Ethics Committee in Australia and is being conducted in healthy volunteers. “The current treatment for asthma and COPD are mainly bronchodilators that relieve symptoms but do not delay the disease progression. ZL-2102 is a first-in-class anti-inflammation new chemical entity that has shown good efficacy and safety in animal models” said Dr. Ning Xu, Executive Vice President of Clinical and Regulatory Affairs at Zai Lab. “Through collaboration with experienced investigators, we will evaluate ZL-2102’s safety and PK profiles in human in single ascending dose, multiple ascending dose, and food effect studies. We look forward to developing a potent drug that could be disease modifying for the long-term treatment of chronic respiratory diseases”

“We are very excited to work with Zai Lab on their first-in-class compound, ZL-2102, which has great potential to fulfill some big unmet medical needs” commented Dr. Janakan Krishnarajah, principal investigator for the trial. “Zai Lab has a great team under the leadership of Dr. Samantha Du who is highly reputable and has a long working relationship with us. I am truly impressed with the fast progress to phase I study that Zai has demonstrated.”

ZL-2102 is one of two novel compounds that Zai Lab licensed from Sanofi in August last year and the first one to enter into clinical study in Australia.

### **About Chronic Respiratory Diseases**

Chronic respiratory diseases are a group of chronic diseases affecting the airway and the other structures of the lungs. Hundreds of millions of people around the world suffer from these diseases. In China, according to WHO, chronic respiratory diseases are the second leading cause of death. It is estimated that over 50% of Chinese men smoke and the worsening pollution levels is also a major contributor.

Chronic Obstructive Pulmonary Disease (COPD) is a condition marked by inflammation and destruction of the airways and lung, typically brought about by longstanding smoking. Persons affected by COPD have prominent symptoms of cough, phlegm, shortness of breath and exercise limitation. Pulmonary exacerbations

(worsening of respiratory symptoms caused principally by viral infections), are a major contributor to the health care costs and serious consequences (hospitalization, death) for COPD patients.

Asthma is a chronic inflammatory disorder of the airways, usually associated with airway hyper-responsiveness and variable airflow obstruction, that is often reversible spontaneously or under treatment.

### **About ZAI Lab**

ZAI Lab is a leading biotech company based in Shanghai focused on discovering and developing innovative medicines for unmet medical needs globally. The company is building a strong portfolio of therapeutic programs aimed at transforming patients' lives. Zai Lab has a world class leadership team with deep experience at global pharmaceutical and biotech organizations. The team has a strong track record of success – successfully took five novel drug candidates into clinical trials in China, pioneered new regulatory channels, secured regulatory approvals in record times, conducted multiple IND trials in the US, and brought the first China discovered drug into Global Phase III trials. Zai Lab is committed to build a globally leading drug discovery and development powerhouse with a culture of excellence and teamwork and a strong focus on fostering innovation and creativity.

For more information, please visit [www.zailaboratory.com](http://www.zailaboratory.com)

For media enquiries, please contact:

ZAI Lab

Jonathan Wang, +86 21 6163 2588

[bd@zailaboratory.com](mailto:bd@zailaboratory.com)